Ocuphire Pharma Investor Update

LO 5 Key Takeaways from Nyxol's MIRA-3 2nd Phase 3 RM Trial MIRA-3 Met Primary Endpoint Key Secondary Endpoints Met Statistical and Clinical Significance MIRA-2 and MIRA-3 topline data. Completed 2 Confirmatory FDA Registration Trials in RM MIRA-3 58% vs. 6% p<0.0001 ✓ MIRA-2 49% vs. 7% p<0.0001 On Track to File Nyxol NDA in RM in Late 2022 Ocuphire PHARMA

View entire presentation